Maxon One Explodes with Exciting New Features and Workflow Improvements
9.11.2022 20:00:00 EET | Business Wire | Press release
Maxon, developers of professional software solutions for editors, filmmakers, motion designers and visual effects artists, today announced several updates to the company’s Maxon One product line. The November 2022 release features a blazingly hot new feature for Cinema 4D - Pyro. Pyro allows artists to create fire, smoke and explosions - easily simulated using GPU or CPU. Other Cinema 4D features include an integrated Redshift Camera and Radial Symmetry for modeling. Forger expands its professional modeling functions by adding Cinema 4D's advanced Symmetry capabilities. The latest release of VFX enhances Real Lens Flares with more natural elements, adding Schmutz and Diffraction effects to the optical simulation. The latest version of Trapcode offers an interactive and updated user interface for Particular's curves and color gradients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221109005139/en/
Maxon One Receives New Features and Improvements in November Release: Cinema 4D receives new Pyro tool, Trapcode Particular shines in an updated UI, the first full version of Real Lens Flares is released and Forger expands professional modeling capabilities. (Graphic: Business Wire)
Cinema 4D 2023.1: Cinema 4D introduces Pyro! for creating fire, smoke and explosions. Seamless integration in Cinema 4D’s Unified Simulation System, means Cloth and Soft Bodies can be set ablaze and fan the flames. A newly integrated RedShift Camera brings intuitive physical camera controls and Redshift effect settings. New Radial Symmetry modeling allows the interactive modeling of anything round by defining a number of slices and offset. And, many more workflow enhancements are included.
Forger: Forger continues to add the comprehensive modeling capabilities of Cinema 4D to iPad with the addition of Symmetry modeling, bringing desktop power and workflows to mobile flexibility.
VFX: The latest version of VFX introduces the first full version of Real Lens Flares adding Schmutz and Diffraction to make lens look grimy and add rippling effects to each lens flare reflection element. Dozens of presents as well as base lens prescriptions have also been added.
Trapcode: Trapcode 2023.1 offers a completely refreshed and upgraded user interface for the Particular curves and color gradients as well as new emitter block presets for Form behaviors and improved performance.
Capsules: Maxon continues to deliver valuable Capsule assets that subscribers can use as a creative kickstart. Artists can now easily compose a product shot with the new Backdrop Primitive, and a new Square Star Spline and FUI Ring Spline create a variety of crosshair and reticule shapes for FUI graphics.
Cineware for Unreal: An updated Cineware for Unreal integration now supports Cinema 4D 2023.1 and Unreal Engine 5.0.3. Easily import C4D files into Unreal and make changes without leaving the engine environment.
About Maxon
Maxon makes powerful, yet approachable software solutions for content creators working in 2D and 3D design, motion graphics, visual effects and visualization. Maxon’s innovative product portfolio helps artists supercharge their creative workflows. Our product lines include the award-winning Cinema 4D suite of 3D modeling, simulation and animation technology; the creativity-on-the-go Forger mobile sculpting app; the diverse Red Giant lineup of revolutionary editing, motion design and filmmaking tools; the leading-edge, blazingly fast Redshift renderer; and ZBrush, the industry-standard digital sculpting and painting solution.
Maxon’s team is comprised of fun, passionate people who believe in building and empowering a successful artistic community. From our popular, inclusive events to our free Cineversity educational resources, Maxon recognizes that developing strong connections with creatives and fostering their professional growth is integral to our ability to stay on top of industry trends and better serve customers.
Maxon is part of the Nemetschek Group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005139/en/
Contact information
Press
Chloe Larby
Grithaus Agency
chloe@grithaus.agency
+44 7454 012045
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
